ViGENCELL is a bio-venture firm engaged in research and development of new pharmaceuticals, as well as the development and manufacturing of immunotherapy drugs. It has established a growth vision to become a leading cell therapy company by utilizing platform technologies for treating various cancers and intractable diseases. The company has successfully proliferated myeloid-derived suppressor cells (MDSCs) from umbilical cord blood, which is rich in an immunoregulatory environment that maintains immune tolerance between mother and fetus, marking the first success in the world. It is currently in the commercialization stage of immunosuppressive cell therapies.

ViTier™ : Platform Technology for Antigen-specific killer T cell therapy ViMedier™ : Platform Technology for cord blood-derived myeloid suppressor cell therapy ViRanger™ : Platform Technology for “Off-the-Shelf” universal T cell gene therapy

Public

Biotech